A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Public ClinicalTrials.gov record NCT01087151. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Randomized, Controlled, Open-label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-intensive Rituximab, or Dose-intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase II, randomized, open-label, international, multicenter trial is designed to evaluate the safety and efficacy of rituximab monotherapy when given according to a dose intense regimen and to assess the safety, efficacy, and pharmacokinetics of ABT-263 when combined with dose-intense rituximab in previously untreated patients with B-cell CLL.
Study identification
- NCT ID
- NCT01087151
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 118 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- May 31, 2012
- Completion
- May 31, 2012
- Last update posted
- Nov 1, 2016
2010 – 2012
United States locations
- U.S. sites
- 48
- U.S. states
- 18
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Alhambra | California | 91801 | — |
| Not listed | Antioch | California | 94531 | — |
| Not listed | Berkeley | California | 94704 | — |
| Not listed | Burbank | California | 91505 | — |
| Not listed | Duarte | California | 91010 | — |
| Not listed | Dublin | California | 94568 | — |
| Not listed | La Jolla | California | 92093 | — |
| Not listed | Los Angeles | California | 90024 | — |
| Not listed | Los Angeles | California | 90073 | — |
| Not listed | Los Angeles | California | 90095-1772 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | Northridge | California | 91325 | — |
| Not listed | Pleasant Hill | California | 94523 | — |
| Not listed | San Leandro | California | 94578-2626 | — |
| Not listed | San Luis Obispo | California | 93454 | — |
| Not listed | Santa Monica | California | 90404 | — |
| Not listed | Fort Collins | Colorado | 80528 | — |
| Not listed | Norwalk | Connecticut | 06856 | — |
| Not listed | Bay Pines | Florida | 33744 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Chicago | Illinois | 60612 | — |
| Not listed | Decatur | Illinois | 62526 | — |
| Not listed | Harvey | Illinois | 60426 | — |
| Not listed | Tinley Park | Illinois | 60477 | — |
| Not listed | Shreverport | Louisiana | 71103 | — |
| Not listed | Baltimore | Maryland | 21215 | — |
| Not listed | Bethesda | Maryland | 20817 | — |
| Not listed | Bethesda | Maryland | 20874 | — |
| Not listed | Randallstown | Maryland | 21133 | — |
| Not listed | Lansing | Michigan | 48909 | — |
| Not listed | Lansing | Michigan | 48912 | — |
| Not listed | Omaha | Nebraska | 68114 | — |
| Not listed | Henderson | Nevada | 89052 | — |
| Not listed | Las Vegas | Nevada | 89148 | — |
| Not listed | Las Vegas | Nevada | 89169 | — |
| Not listed | Reno | Nevada | 89502 | — |
| Not listed | Cherry Hill | New Jersey | 08003 | — |
| Not listed | Farmington | New Mexico | 87401 | — |
| Not listed | Oneida | New York | 13421 | — |
| Not listed | Oswego | New York | 13126 | — |
| Not listed | Syracuse | New York | 13210 | — |
| Not listed | Middletown | Ohio | 45042 | — |
| Not listed | Philadelphia | Pennsylvania | 19111 | — |
| Not listed | Pittsburgh | Pennsylvania | 15224 | — |
| Not listed | Corpus Christi | Texas | 78405 | — |
| Not listed | Lubbock | Texas | 79410 | — |
| Not listed | Lubbock | Texas | 79415 | — |
| Not listed | Everett | Washington | 98201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
Recently updated Chronic Lymphocytic Leukemia trials
Other public records listing Chronic Lymphocytic Leukemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07796373: Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Not yet recruiting
- NCT07516093: Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL Recruiting
- NCT07520006: Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies Recruiting
- NCT03737981: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia Active, not recruiting
- NCT02048813: Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting
- NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01087151, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01087151 live on ClinicalTrials.gov.